L.N. 41 of 2020

Section 1

Pharmacy and Poisons (Amendment) (No. 2) Regulation 2020

(Made by the Pharmacy and Poisons Board under section 29(1B) of the Pharmacy and Poisons Ordinance (Cap. 138) subject to the approval of the Secretary for Food and Health)

1. Pharmacy and Poisons Regulations amended

The Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) are amended as set out in sections 2, 3 and 4.

- 2. Schedule 1 amended (substances to which certain restrictions with respect to the sale, supply, labelling and storage apply under regulations 3, 5, 6, 22 and 24)
 - (1) Schedule 1, Division A, after item "Bupropion; its salts"—

 Add

"Burosumab".

(2) Schedule 1, Division A, after item "Entecavir; its salts; its esters; their salts"—

Add

"Entrectinib; its salts".

(3) Schedule 1, Division A, after item "Liraglutide"—

Add

"Lisdexamfetamine; its salts".

(4) Schedule 1, Division A, after item "Lurasidone; its salts"—

Add

"Lutetium (177Lu) oxodotreotide; its salts".

(5) Schedule 1, Division A, after item "Plerixafor; its salts"—

Add

"Polatuzumab vedotin".

(6) Schedule 1, Division A, after item "Pramipexole; its salts"—

Add

"Prasterone; its salts; when contained in pharmaceutical products".

- 3. Schedule 3 amended (substances required by regulation 9 to be sold by retail only upon a prescription given by a registered medical practitioner, registered dentist or registered veterinary surgeon)
 - (1) Schedule 3, Division A, after item "Bupropion; its salts"—

 Add

"Burosumab".

(2) Schedule 3, Division A, after item "Entecavir; its salts; its esters; their salts"—

Add

"Entrectinib; its salts".

(3) Schedule 3, Division A, after item "Liraglutide"—

Add

"Lisdexamfetamine; its salts".

(4) Schedule 3, Division A, after item "Lurasidone; its salts"—

Add

"Lutetium (177Lu) oxodotreotide; its salts".

(5) Schedule 3, Division A, after item "Plerixafor; its salts"—

Add

"Polatuzumah vedotin"

(6) Schedule 3, Division A, after item "Pramipexole; its salts"—

Add

"Prasterone; its salts; when contained in pharmaceutical products".

4. Schedule 10 amended (Poisons List)

(1) Schedule 10, section 2, Table, Part 1, Division A, after item "Bupropion; its salts"—

Add

"Burosumab".

(2) Schedule 10, section 2, Table, Part 1, Division A, after item "Entecavir; its salts; its esters; their salts"—

Add

"Entrectinib; its salts".

(3) Schedule 10, section 2, Table, Part 1, Division A, after item "Liraglutide"—

Add

"Lisdexamfetamine; its salts".

(4) Schedule 10, section 2, Table, Part 1, Division A, after item "Lurasidone; its salts"—

Add

"Lutetium (177Lu) oxodotreotide; its salts".

(5) Schedule 10, section 2, Table, Part 1, Division A, after item "Podophyllum resin"—

Add

"Polatuzumab vedotin".

(6) Schedule 10, section 2, Table, Part 1, Division A, after item "Pramoxine; its salts"—

Add

"Prasterone; its salts; when contained in pharmaceutical products".

Dr. Constance CHAN
Chairman,
Pharmacy and Poisons Board

1 April :	2020		

L.N. 41 of 2020 B657

Explanatory Note

This Regulation amends the Pharmacy and Poisons Regulations (Cap. 138 sub. leg. A) to add 6 items to—

- (a) Division A of Schedule 1;
- (b) Division A of Schedule 3; and
- (c) Division A of Part 1 of the Poisons List set out in Schedule 10.
- 2. The amendments relate to requirements concerning sale, supply, labelling and storage. Main effects of the amendments include—
 - (a) that the sale, by retail, of substances specified in the 6 items—
 - (i) may only be effected on registered premises of an authorized seller of poisons by a registered pharmacist or in the presence and under the supervision of a registered pharmacist; and
 - (ii) may only be effected on and in accordance with a prescription by a registered medical practitioner, registered dentist or registered veterinary surgeon; and
 - (b) that the substances, if stored in retail premises, must be stored in a part of the premises to which customers are not permitted access.